pharma · Acute Pain
Menarini
Menarini Group
Menarini Group is a pharma organization headquartered in CN. Primary therapeutic focus areas include Acute Pain. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from p
Company details
- Status
- Public
- HQ
- Firenze, IT
- Employees
- 12,911
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Quick answer
Menarini Group is a pharma organization headquartered in CN. Primary therapeutic focus areas include Acute Pain. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1).
Company snapshot
The Menarini Group is an Italian [pharmaceutical](en.wikipedia.org/wiki/Pharmaceutical) company. Its headquarters is in [Florence](en.wikipedia.org/wiki/Florence), [Tuscany](en.wikipedia.org/wiki/Tuscany), and it has three divisions: Menarini Ricerche, Menarini Biotech, and Menarini Diagnostics. It develops pharmacological solutions for [cardiovascular diseases](en.wikipedia.org/wiki/Cardiovascula
- 1 active pipeline program(s) linked via ClinicalTrials.gov.
- 1 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Menarini. Not investment advice.
Top assets
Active clinical programs
- Phase 3
Momentum signals
Momentum
Proprietary activity score for Menarini.
1 active signal
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitive landscape
Recent activity
Recent activity
Latest pipeline, patent, and corporate events for Menarini.
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Menarini?
-
Is Menarini publicly traded?
-
What drugs does Menarini develop or market?
-
What are the latest developments for Menarini?
-
What therapeutic areas does Menarini focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.